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Abstract
Objective Gastro-oesophageal reflux disease (GORD) is
a common comorbidity among patients with rheumatoid
arthritis (RA). While GORD has been attributed to the
antirheumatic medications, no studies of human cohorts
have investigated a link between GORD and RA. This
study investigates whether GORD is associated with a
subsequent RA diagnosis over a 5-year follow-up using a
population-based dataset.
Setting Taiwan
Participants We used data from the Taiwan Longitudinal
Health Insurance Database. The study group consisted of
13 645 patients with an ambulatory claim showing a GORD
diagnosis. We used propensity score matching to select
13 645 comparison patients (one per study patient with
GORD).
Intervention We tracked each patient’s claims over a
5-year period to identify those who subsequently received
a diagnosis of RA. Cox proportional hazard (PH) regression
modelling was used for analysis.
Results Over 5-year follow-up, RA incidence rate per
1000 person-years was 2.81 among patients with GORD
and 0.84 among the comparison group. Cox PH modelling
showed that GORD was independently associated with
a 2.84-fold increased risk of RA (95% CI 2.09 to 3.85)
over 5-year follow-up, after adjusting for the number of
ambulatory care visits within the year following the index
date (to mitigate surveillance bias).
Conclusions We observed that GORD might associate
with subsequent RA occurrence. Because current
treatment guidelines for RA emphasise early diagnosis
and prompt treatment, the observed association between
GORD and RA may help acquaint clinicians to patients with
GORD with higher RA risk and facilitate early diagnosis and
treatment.

Introduction
Rheumatoid arthritis (RA) is one of the
most widely prevalent chronic inflammatory diseases. Although predominantly
involving the joints, RA is recognised as
a systemic condition with extra-articular

Strengths and limitations of this study
►► This study used a population-based dataset.
►► The large sample size provided appropriate

statistical power to detect real differences between
the two groups.
►► The dataset used lacks clinical information and
therefore did not allow us to distinguish study
patients according to the severity of their gastrooesophageal reflux disease or rheumatoid arthritis.
►► As no standardised criteria were used to define
cases, some room for bias may have existed due to
case misclassification.

manifestations.1 RA affects about 0.5%–1%
of the adult population and is associated with
progressive worsening of joint function and
increased morbidity and mortality.2–4 Due
to musculoskeletal deficits, patients with RA
may experience cumulative comorbidity risks,
deteriorating physical function, declining
quality of life and substantial medical and
socioeconomic burdens.5 6 Upper gastrointestinal (GI) disease is a recognised, major
comorbidity associated with RA and contributes to the increased mortality risk of patients
with RA.7–11Gastro-oesophageal reflux disease
(GORD) is a widely prevalent disorder of
the GI tract. It manifests with major upper
GI symptoms, heartburn and acid regurgitation due to reflux of gastric contents into
the oesophagus.12 A study from Japan documented a higher prevalence of GORD among
patients with RA compared with the general
population (24.6% vs 11.5%).13 A study from
the USA showed that GORD was more likely
among patients with RA aged <60 years.14 Antirheumatic medications (particularly, non-steroidal anti-inflammatory drugs (NSAIDs))
have been blamed for the increased burden
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Methods
Database
Sample patients were selected from the Taiwan Longitudinal Health Insurance Database 2005 (LHID2005),
hosted by the Taiwan National Health Research Institutes.
Taiwan implemented its National Health Insurance (NHI)
programme in 1995. The LHID2005 contains registration
files and all medical care claims for 1 000 000 enrollees
randomly selected from all enrollees (n=23.72 million)
listed in the 2005 Registry of NHI Beneficiaries. The
LHID2005 allows researchers to longitudinally track
medical services provided to the selected enrollees since
NHI inception in 1995.
This study was exempt from full review by the Institutional Review Board of Taipei Medical University
(TMU-JIRB 201612025) since the LHID2005 consists of
de-identified secondary data released without restriction
to researchers for research purposes.
Study sample
This nested case–control study included a study group and
a comparison group. To select the study group, we first
retrieved 21 395 patients who visited clinics or ambulatory
care centres for the treatment of GORD (International
2

Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 530.11 or 530.81) between
1 January 2002 and 21 December 2008. We excluded
paediatric patients (<18 years of age, n=594) in order
to limit the sample to the adult population. To improve
the validity of the GORD diagnoses, we included only
those patients who were diagnosed by either endoscopy
or 24 hour pH monitoring, and additionally, received a
proton-pump inhibitor prescription for more than 30
days (n=13 977). We assigned the first date of the GORD
diagnosis as the index date for study patients. Finally, we
excluded 332 patients with GORD who had a diagnosis
of RA (ICD-9-CM code 714.0) preceding the index date
of the GORD diagnosis. The final study group included
13 645 patients with GORD.
To select comparison patients from the remaining
patients of the LHID2005 dataset, we first excluded
patients with any claim showing a diagnosis of GORD
since initiation of the NHI program in 1995 and all paediatric patients. We used propensity score matching to select
13 645 comparison patients (one for every study patient
with GORD). The selected variables, age, sex, monthly
income (NT$0~15 840, NT$15 841~25 000≥NT$25 001;
average exchange rate in 2008, US$1.00≈New Taiwan
(NT)$29), geographical location (Northern, Central,
Southern and Eastern), urbanisation level of the patient’s
residence, the year of the index date and medical comorbidities, were entered into a multivariable logistic regression model as predictors to calculate each patient’s
expected probability of receiving a GORD diagnosis. Residential urbanisation level is classified by the Taiwanese
National Health Research Institute into five levels (one
being the most urbanised and five least urbanised).
Medical comorbidities were identified using ICD-9-CM
codes and included hyperlipidaemia (272.0–272.4),
diabetes (250), hypertension (401–405), coronary heart
disease (410–414 or 429.2), stroke (430–438) and obesity
(278, 278.0, 278.00 or 278.01). The diagnosis of tobacco
use disorder (305.1) in the claims data was used to identify severe current smokers. These comorbid conditions
were included only if the condition occurred in an inpatient claim or in two or more ambulatory care claims
within 2 years before the index date.
For the study group, the year of the index date was the
year in which they received their first-time diagnosis of
GORD. To create the comparison group, comparison
patients were selected based on matched propensity
scores for receiving a GORD diagnosis. We then assigned
their first healthcare use that occurred in the index year
of the matched study patient as the index date for the
comparison patient. All comparison patients’ prior claims
were screened to ensure that none of them had a history
of RA prior to their index date.
The study included 13 645 study patients and 13 645
comparison patients. We tracked each patient’s claims
over a 5-year period from their index date to identify those
who subsequently received a diagnosis of RA (ICD-9-CM
code 714.0). To enhance validity of the RA diagnosis, we
Lin H-C, et al. BMJ Open 2017;7:e016667. doi:10.1136/bmjopen-2017-016667
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of GI diseases among patients with RA.15–17 An alternative
hypothesis has been recently proposed that GI disorders
may be part of the clinical spectrum and pathogenesis of
RA disease.9 18
The link between GORD and RA may extend beyond
shared pathogenic processes. As is well documented,
both genetic (eg, heritability and family history3 19)
and environmental factors (eg, smoking and low socioeconomic status or educational attainment20 21) are
involved in the pathogenesis of RA.22 Recent studies have
suggested a role of the microbiome in RA risk and its
progression.23 24 Studies based on animal models suggest
a prominent role of the gut microbiome in the progression of RA.23 Evidence for the immunological relevance
of peptides from gut microbes was strengthened by their
detection in synovial tissues and peripheral blood mononuclear cells among patients with newly diagnosed RA.25
As these evidences examined mainly on lower GI, none
has attempted to investigate the potential role of upper
GI tract microbiomes (eg, GORD) on RA development.
Nevertheless, it would be plausible that chronic inflammation resulting from the repeated acid reflux in GORD
may cause mucosal damage and translocation of the
microbiome from the gut into the circulation,26 27 GORD
may therefore serve as a facilitating factor for RA pathogenesis, a hypothesis that could be tested by looking for
evidence that GORD predates RA and that GORD is associated with disproportionately more new RA diagnoses
than among persons without GORD. This study investigates whether GORD is associated with increased risk of
a subsequent RA diagnosis over 5-year follow-up using a
population-based dataset.

Open Access

Statistical analysis
We used the SAS system for statistical analyses. We used
Pearson’s Χ2 tests to examine differences between GORD
patients and comparison patients on sociodemographic
characteristics and medical comorbidities. We performed
a log-rank test to examine the difference in 5-year RA-free
survival between the two groups. We performed Cox
proportional hazard regressions to calculate the HR and
95% CI for the subsequent occurrence of RA over 5-year
follow-up.
We verified that the data were consistent with the
proportional hazards assumption by confirming that the
survival curves for both strata (GORD and comparison
patients) had hazard functions that were proportional
over time. Finally, we censored patients who died or were
lost to follow-up during the study (787 study patients

(5.77% of patients with GORD) and 801 comparison
patients (5.87% of the comparison group)). A significance level of 0.05 was used.

Results
Table 1 shows the sample demographic distribution
stratified by the presence or absence of GORD. Because
of propensity score matching, there was no significant
difference in age, sex, monthly income, urbanisation
level, geographic region and medical comorbidities
between patients with GORD and comparison patients
(all p>0.05). However, there was a significant difference
in the number of ambulatory care visits within 1 year of
the index date (p<0.001).
The incidence of RA during 5-year follow-up is
presented in table 2. RA incidence was 2.81 (2.42–3.24)
per 1000 person-years of observation among patients

Table 1 Demographic and clinical characteristics of sampled patients (n=27 290)
Patients who received a diagnosis
of GORD, n=13 645

Comparison patients n=13 645

Variable

Total number

Column %

Total number

Column %

p Value

Males
Age, mean (SD)

6490
48.2±15.0

47.6

6474
48.1±16.1

47.5

0.846
0.064

4512

33.1

4430

32.5

0.780

Urbanisation level
 1 (most)
 2

3852

28.2

3907

28.6

 3

1964

14.4

2011

14.7

 4

1827

13.4

1817

13.3

 5 (least)

1490

10.9

1480

10.9

Monthly income
 NT$0–15 840

4688

34.4

4782

35.0

 NT$15 841–25 000

4800

35.2

4837

35.5

 ≥NT$25 001

4157

30.5

4026

29.5

6615

48.5

6707

49.1

0.204

Geographical region
 Northern
 Central

4013

29.4

3827

28.0

 Southern

2724

20.0

2740

20.1

293

2.1

281

1.8

 Eastern

0.168

Hypertension

4218

30.9

4121

30.2

0.202

Diabetes

1922

14.1

1864

13.7

0.310

428

3.1

392

2.9

0.202

Tobacco use disorder

4095

30.0

3976

29.1

0.114

Obesity

Hyperlipidaemia

245

1.8

219

1.6

0.223

Stroke

1240

9.1

1165

Coronary heart disease
Number of ambulatory care visits
within 1 year after index date

1483
28.6±22.6

10.9

1473
18.7±18.1

8.5

0.109

10.8

0.846
<0.001

Note: The average exchange rate in 2008 was US$1.00≈New Taiwan (NT)$29.
GORD, gastro-oesophageal reflux disease.
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identified only those patients who showed a RA diagnosis
in at least two distinct medical encounter claims.
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Patients who received
a diagnosis of GORD,
n=13 645

Presence of RA

Total sample, n=27 290

Five-year follow-up period
Yes, n (%)

242 (0.89)

186 (1.36)

Incidence rate per 1000 personyears (95% CI)

1.82 (1.60 to 2.06)

2.81 (2.42 to 3.24)

HR (95% CI)
Adjusted HR* (95% CI)

–

Comparison patients,
n=13 645
56 (0.41)

3.35*** (2.48 to 4.52)
2.84*** (2.09 to 3.85)

0.84 (0.64 to 1.09)
1.00
1.00

*Adjustments were made for the number of ambulatory care visits within 1 year after the index date.
The HR was calculated by a Cox proportional hazard regression.
***p<0.01.
GORD, gastro-oesophageal reflux disease.

with GORD and 0.84 (0.64–1.09) per 1000 person-years
among comparison patients. The log-rank test showed
that patients with GORD were more likely to be diagnosed
with RA than comparison patients (p<0.001). Table 2
also shows the Cox HRs for RA. The HR for RA among
patients with GORD relative to comparison patients over
5-year follow-up was 2.84 (95% CI 2.09 to 3.85) after
censoring deaths and loss to follow-up and adjusting for
the number of ambulatory care visits within 1 year of the
index date. For the 242 sample patients who received an
RA diagnosis during the follow-up, the mean gap between
the index date and RA diagnosis was 756 days (SD 502
days), being 839 and 481 days, respectively, for patients
with and without GORD.
We conducted a stratified proportional hazard analysis,
stratifying on sex (table 3). For females with GORD, the
HR for RA was higher (adjusted HR 3.36, 95% CI 2.30 to
4.91) than males (adjusted HR 2.00, 95% CI=1.18 to 3.37).
We used sensitivity analysis to assess the possible role
of surveillance bias, which may increase the likelihood of

chronically ill patients being subsequently diagnosed with
other diseases due to their greater frequency of medical
encounters than healthier patients. Patients with GORD
may visit doctors more often than comparison patients
and therefore have a greater chance of being diagnosed
with RA, while those in the comparison group may disregard mild symptoms and remain undetected for some
time. Table 4 presents the results of sensitivity analysis.
After excluding patients who were newly diagnosed with
RA within 60 days following the index date and adjusting
for the number of ambulatory care visits in the first year
of follow-up, the adjusted HR was 2.81 (95% CI 2.06 to
3.83), closely similar to the unadjusted HR.
Discussion
To our knowledge, this study is the first to investigate the
5-year risk of RA among patients with GORD. Propensity score matching (using age, sex, monthly income,
geographical location, residential urbanisation level, year

Table 3 HRs for rheumatoid arthritis (RA) during the 5-year follow-up period by sex
Sex

Development of
RA

Males

Females

Patients who
received a diagnosis
of GORD,
Comparison patients,
(n=6490) n, %
(n=6474) n, %

Patients who received a
diagnosis of GORD
(n=7155) n, %

Five-year follow-up period
Yes
50
Incidence rate per
1000 person-years
(95% CI)
HR (95% CI)
Adjusted HR*
(95% CI)

0.77

21

0.32

1.58 (1.18 to 2.09) 0.68 (0.42 to 1.04)

2.39*** (1.43 to 3.98)
2.00*** (1.18 to 3.37)

1.00
1.00

136

1.90

3.93 (3.29 to 4.64)

3.95*** (2.72 to 5.74)
3.36*** (2.30 to 4.91)

Comparison patients,
(n=7171) n, %
35

0.49

0.98 (0.68 to 1.36)

1.00

*Adjustments were made for the number of ambulatory care visits within 1 year after the index date.
The HR was calculated by a Cox proportional hazard regression.
***p<0.01.
GORD, gastro-oesophageal reflux disease.

4

Lin H-C, et al. BMJ Open 2017;7:e016667. doi:10.1136/bmjopen-2017-016667

BMJ Open: first published as 10.1136/bmjopen-2017-016667 on 17 November 2017. Downloaded from http://bmjopen.bmj.com/ on July 1, 2020 by guest. Protected by copyright.

Table 2 HRs for rheumatoid arthritis (RA) among sampled patients during the 5-year follow-up period

Open Access

Presence of RA

Total sample, n=27 279

Five-year follow-up period
Yes, n (%)

231 (0.85)

HR (95% CI)
Adjusted HR* (95% CI)

–

Patients who received
a diagnosis of GORD,
n=13 636
177 (1.30)
3.31*** (2.43 to 4.49)
2.81*** (2.06 to 3.83)

Comparison patients,
n=13 643
54 (0.40)
1.00
1.00

*Adjustments were made for the number of ambulatory care visits within 1 year after the index date.
The HR was calculated by a Cox proportional hazard regression.
***p<0.01.
GORD, gastro-oesophageal reflux disease.

of the index date and medical comorbidities) was done
to select comparison patients without GORD in order to
mitigate selection bias. During the 5-year follow-up, we
documented RA incidence per 1000 person-years of 2.81
for patients with GORD and 0.84 for comparison patients.
We also observed that after mitigating surveillance bias,
GORD was independently associated with 2.84-fold higher
risk of RA during 5-year follow-up, after adjusting for the
number of ambulatory care visits within 1 year of the
index date. Our findings may support previously documented animal model evidence that implicated a pathogenetic role of GORD in RA risk and its progression.
Upper GI diseases are major comorbid medical conditions contributing to the impaired quality of life and
increased mortality risk experienced by patients with
RA.7-11
A Japanese study specifically linked RA with GORD,
a common GI condition among patients with RA. The
authors reported that the prevalence of GORD was
significantly higher among patients with RA, compared
to the general population.13 GI disease has been, thus far,
considered an adverse effect of RA treatment, particularly
NSAIDs.15 16 28 29 No study has examined whether GORD is
simply a comorbid illness occurring after the RA diagnosis
due to treatment. In recent years, it has been suggested
that GORD may be implicated at a much earlier stage in
shaping the disease risk, in light of increasing research
on the role of environmental factors in the pathogenesis
of RA (eg, microbiome effects23 24). Our study presents
epidemiological evidence that GORD is associated with a
subsequent RA diagnosis over 5-year follow-up. Given that
GORD predated the RA diagnosis by a substantial period
of time (more than 2 years in average), it appears unlikely
that GORD was merely an early manifestation of underlying, asymptomatic RA pathology.
In additional analysis that classified the sample by sex,
we observed that the RA increased RA risk of patients
with GORD relative to comparison patients is heightened
among females (males OR 2.00, 95% CI 1.18 to 3.37;
females OR 3.36, 95% CI 2.30 to 4.91). The magnitude of
difference between the sexes is consistent with the known
sex bias of RA incidence; approximately 70% of patients
Lin H-C, et al. BMJ Open 2017;7:e016667. doi:10.1136/bmjopen-2017-016667

with RA are women.30 No statistically significant findings
were observed on stratification by age.
How the RA risk is intensified among patients with
GORD has not been articulated. Tentative evidence,
though mainly focusing on lower GI, suggests the possibility that the microbiome may play a role in many autoimmune diseases, including RA.23 24 Clinical studies and
laboratory research have investigated various factors
in the pathogenesis of RA, including environmental
factors, genetic factors and inflammatory pathways. One
currently prevailing hypothesis is that specific organisms
in the mouth or gut microbiota may influence mucosal
and systemic immune responses affecting the joints in
patients with RA.31–33 Stool samples from patients with
recent-onset RA, compared with patients with chronic
RA, psoriatic arthritis or healthy individuals, show that
Prevotella copri in the gut microbiota is overmagnified.34
While dysbiosis is documented in patients with RA,35 a
recent study in mice confirmed that dysbiosis contributes
to arthritis development through activation of autoreactive T cells in the intestines.36 Alterations in microbial
populations in oral, salivary and other GI sites that were
associated with C-reactive protein and autoantibodies
against citrullinated peptides status and were also identified in human patients.37 Further, by liquid chromatography tandem mass spectrometry, Pianta et al attempted
to examine whether overmagnification of P. copri in the
gut of human patients may alter immune cell functions
at both mucosal and systemic sites, contributing to the
pathogenesis of RA disease.25 They found that among
42% of patients with RA, Th1 responses could be stimulated in vivo by an human leucocyte antigen-antigen D
related-presented peptide stemming from a P. copri 27-kD
protein (Pc-p27). P. copri provoked differential antibody
responses to the whole organism or this specific protein
in a considerable fraction of patients with RA. As this
evidence on lower GI revealed the immunological relevance of the microbiota in the pathogenesis of RA, none
has attempted to examine the role of upper GI illnesses,
such as GORD in our study. How the occurrence of GORD
may be linked with RA remains unknown. But presumably, GORD, a chronic oesophageal injury that occurs due
5
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diagnosis of tobacco use disorder in the claims data was
used to account for severe smoking behaviours, while
leaving less intense smoking unaccounted for in the analysis. Another unavoidable confounder in retrospective
studies is that patients with arthralgia or joint symptoms
may consume more NSAIDS which directly increases the
risk of GORD. Information on the prior existence of such
conditions and on NSAID consumption or other relevant
medications is not available in the dataset. Therefore,
the current study design does not permit an unequivocal
inference of a causal relationship between GORD and
RA. Finally, the generalisability of our study findings may
be limited to ethnic Chinese populations. Future studies
will need to include other ethnic groups for evaluation.
Our findings extend the significance and implications of
previously reported evidence regarding comorbid GORD
among RA. It offers evidence that GORD, a common GI
disease, is associated with increased risk of subsequent
RA occurrence, using a large, population-based, national
dataset. Although our exploratory study offers epidemiological evidence of an association using a retrospective
case–control approach, replication of the finding in
other settings is required, as well as studies to better characterise the link and verify the directionality and causal
link, if any. Biomedical research is essential to elucidate
the underlying pathways connecting GORD with RA to
interpret the clinical significance of these epidemiological findings.
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to intermittent, abnormal reflux of gastric contents into
the oesophagus, may damage the oesophageal mucosa.38
Bacteria may then be translocated from the gut to the
bloodstream and induce immune responses.26 Bacterial
translocation, defined as the movement of viable bacteria
from the gastrointestinal tract to extraintestinal locations
such as the bloodstream, may be promoted through three
mechanisms of: (a) intestinal bacterial overgrowth, (b)
augmented permeability of the intestinal mucosal barrier
and (c) deficits in host immune defences.26 27 GORD may,
therefore, be associated with a subsequently increased RA
risk, as observed in our epidemiological study. The pathobiological pathways underlying these observations remain
unknown and should be explored in future studies.
Our findings have important clinical and public health
implications for managing GORD. Typically, patients with
RA exhibit tender and swollen joints of recent onset,
morning joint stiffness, and abnormal laboratory findings such as elevated blood levels of C-reactive protein or
erythrocyte sedimentation rates. However, none of these
features are specific to RA, which impedes early diagnosis
in many patients. Given that early diagnosis and prompt
treatment of RA is emphasised,1 the treating medical
team, if aware of the possible pathogenic link, may be
able to arrive at the diagnosis sooner and initiate appropriate treatment.
A unique strength of this study was the use of a population-based dataset, which allowed us to track all cases of
GORD and RA during the study period. Moreover, the
large sample size provided adequate statistical power to
detect differences between the two groups.
Despite the strengths, the findings should be interpreted with caution due to certain limitations. First, an
inherent limitation of a claims dataset is that only patients
who sought medical treatment for GORD and RA were
represented in this study. It is unlikely that incident cases
of RA were missed because of the joint swelling, pain and
discomfort that significantly impacts daily functioning,
causing patients to seek medical care. Another potential
source of bias is diagnostic misclassification of GORD
or RA. In the absence of standardised criteria to define
cases, GORD is particularly liable to be underdiagnosed
due to its wide range and severity of manifestations and
subjective perceptions of patients some of whom may not
seek treatment.39 Such misclassification of GORD status
would result in more undiagnosed patients with GORD
among the comparison group and would potentially bias
our results towards the null. Plausibly, therefore, the
actual hazard of RA among patients with GORD may be
higher than the observed HR in our study.
Second, the claims dataset lacks clinical information
and did not allow us to distinguish study patients by
the severity of GORD or RA. Third, there is no data on
personal history such as family history of RA, body mass
index, history of previous infections, exposure to air
pollution and insecticides and occupational exposure to
mineral oil or silica, which may contribute to RA.1 Given
that smoking is an important risk factor for RA,21 40 the
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